DOE Patents title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Prostate cancer-associated secreted proteins

Abstract

Methods are provided for treating a subject with prostate cancer and/or diagnosing a subject at risk for prostate cancer, which can include measuring increased expression of at least two prostate cancer-related molecules in a sample obtained from a subject, including the prostate cancer-related molecules AGR2, AGR3, CRISP3, CCL3, CEACAM5, CEACAM6, IL24, MMP9, CXCL14, CD90, POSTN, and SFRP4. The methods can include administering at therapy to a subject with prostate cancer. Methods are provided for treating a subject with intermediate- or high-risk prostate cancer, which can include measuring increased expression of MMP9 in a sample obtained from a subject compared to a control representing expression of MMP9 expected in a sample from a subject who has low-risk prostate cancer.

Inventors:
; ;
Issue Date:
Research Org.:
Pacific Northwest National Lab. (PNNL), Richland, WA (United States)
Sponsoring Org.:
USDOE
OSTI Identifier:
1735077
Patent Number(s):
10725053
Application Number:
15/839,635
Assignee:
Battelle Memorial Institute (Richland, WA); University of Washington (Seattle, WA)
Patent Classifications (CPCs):
G - PHYSICS G01 - MEASURING G01N - INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
C - CHEMISTRY C12 - BIOCHEMISTRY C12Q - MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
DOE Contract Number:  
AC05-76RL01830
Resource Type:
Patent
Resource Relation:
Patent File Date: 12/12/2017
Country of Publication:
United States
Language:
English

Citation Formats

Qian, Wei-Jun, Shi, Tujin, and Liu, Alvin Y. Prostate cancer-associated secreted proteins. United States: N. p., 2020. Web.
Qian, Wei-Jun, Shi, Tujin, & Liu, Alvin Y. Prostate cancer-associated secreted proteins. United States.
Qian, Wei-Jun, Shi, Tujin, and Liu, Alvin Y. Tue . "Prostate cancer-associated secreted proteins". United States. https://www.osti.gov/servlets/purl/1735077.
@article{osti_1735077,
title = {Prostate cancer-associated secreted proteins},
author = {Qian, Wei-Jun and Shi, Tujin and Liu, Alvin Y.},
abstractNote = {Methods are provided for treating a subject with prostate cancer and/or diagnosing a subject at risk for prostate cancer, which can include measuring increased expression of at least two prostate cancer-related molecules in a sample obtained from a subject, including the prostate cancer-related molecules AGR2, AGR3, CRISP3, CCL3, CEACAM5, CEACAM6, IL24, MMP9, CXCL14, CD90, POSTN, and SFRP4. The methods can include administering at therapy to a subject with prostate cancer. Methods are provided for treating a subject with intermediate- or high-risk prostate cancer, which can include measuring increased expression of MMP9 in a sample obtained from a subject compared to a control representing expression of MMP9 expected in a sample from a subject who has low-risk prostate cancer.},
doi = {},
journal = {},
number = ,
volume = ,
place = {United States},
year = {2020},
month = {7}
}

Works referenced in this record:

Free prostate-specific antigen in serum is becoming more complex
journal, June 2002


Systematic evaluation of quantotypic peptides for targeted analysis of the human kinome
journal, August 2014


Human matrix metalloproteinase-9 : activation by limited trypsin treatment and generation of monoclonal antibodies specific for the activated form
journal, November 1998


Processing of voided urine for prostate cancer RNA biomarker analysis: Urinary RNA Analysis
journal, August 2015


Urinary PSA: a potential useful marker when serum PSA is between 2.5 ng/mL and 10 ng/mL
journal, March 2013


Identification of Prostate-Enriched Proteins by In-depth Proteomic Analyses of Expressed Prostatic Secretions in Urine
journal, February 2012


SV40-transformed Human Lung Fibroblasts Secrete a 92-kDa Type IV Collagenase Which Is Identical to That Secreted by Normal Human Macrophages
journal, October 1989


Identification of a Novel Proteoform of Prostate Specific Antigen (SNP-L132I) in Clinical Samples by Multiple Reaction Monitoring
journal, July 2013


Development of an ELISA to detect the secreted prostate cancer biomarker AGR2 in voided urine: Prostate Cancer Biomarker AGR2
journal, November 2011


Serum proteomics reveals systemic dysregulation of innate immunity in type 1 diabetes
journal, December 2012


Development of selected reaction monitoring-MS methodology to measure peptide biomarkers in prostate cancer
journal, September 2010


Innovations in Serum and Urine Markers in Prostate Cancer
journal, December 2005


Multiplexed targeted mass spectrometry assays for prostate cancer-associated urinary proteins
journal, October 2017


Targeted Quantification of Low ng/mL Level Proteins in Human Serum without Immunoaffinity Depletion
journal, June 2013


Quantitative, Multiplexed Assays for Low Abundance Proteins in Plasma by Targeted Mass Spectrometry and Stable Isotope Dilution
journal, October 2007


Selected reaction monitoring assays
patent, July 2015


Antibody-free, targeted mass-spectrometric approach for quantification of proteins at low picogram per milliliter levels in human plasma/serum
journal, September 2012


A Highly Sensitive Targeted Mass Spectrometric Assay for Quantification of AGR2 Protein in Human Urine and Serum
journal, December 2013


PCA3 Molecular Urine Assay Correlates With Prostate Cancer Tumor Volume: Implication in Selecting Candidates for Active Surveillance
journal, May 2008